DK3723858T3 - Fixaxfx bispecifik antistof med fælles let kæde - Google Patents

Fixaxfx bispecifik antistof med fælles let kæde Download PDF

Info

Publication number
DK3723858T3
DK3723858T3 DK19836806.0T DK19836806T DK3723858T3 DK 3723858 T3 DK3723858 T3 DK 3723858T3 DK 19836806 T DK19836806 T DK 19836806T DK 3723858 T3 DK3723858 T3 DK 3723858T3
Authority
DK
Denmark
Prior art keywords
fixaxfx
light chain
bispecific antibody
common light
common
Prior art date
Application number
DK19836806.0T
Other languages
Danish (da)
English (en)
Inventor
Wei Wang
E-Chiang Lee
John Kenneth Blackwood
Roberto Magliozzi
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1820977.5A external-priority patent/GB201820977D0/en
Priority claimed from GBGB1906816.2A external-priority patent/GB201906816D0/en
Priority claimed from GBGB1908190.0A external-priority patent/GB201908190D0/en
Application filed by Kymab Ltd filed Critical Kymab Ltd
Application granted granted Critical
Publication of DK3723858T3 publication Critical patent/DK3723858T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK19836806.0T 2018-12-21 2019-12-20 Fixaxfx bispecifik antistof med fælles let kæde DK3723858T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1820977.5A GB201820977D0 (en) 2018-12-21 2018-12-21 Fixaxfx bispecific antibody with commomn light chain
GBGB1906816.2A GB201906816D0 (en) 2019-05-15 2019-05-15 FIXaxFX bispecific antibody with common light chain
GBGB1908190.0A GB201908190D0 (en) 2019-06-07 2019-06-07 Fixaxfx bispecific antibody with common light chain
PCT/EP2019/086808 WO2020128049A1 (en) 2018-12-21 2019-12-20 Fixaxfx bispecific antibody with common light chain

Publications (1)

Publication Number Publication Date
DK3723858T3 true DK3723858T3 (da) 2022-01-24

Family

ID=69167786

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19836806.0T DK3723858T3 (da) 2018-12-21 2019-12-20 Fixaxfx bispecifik antistof med fælles let kæde

Country Status (18)

Country Link
US (3) US20220064327A1 (cg-RX-API-DMAC7.html)
EP (2) EP4015538A1 (cg-RX-API-DMAC7.html)
JP (1) JP7530362B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210118085A (cg-RX-API-DMAC7.html)
CN (1) CN113453757B (cg-RX-API-DMAC7.html)
BR (1) BR112021012065A2 (cg-RX-API-DMAC7.html)
CA (1) CA3123177A1 (cg-RX-API-DMAC7.html)
DK (1) DK3723858T3 (cg-RX-API-DMAC7.html)
ES (1) ES2901683T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220088T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057634T2 (cg-RX-API-DMAC7.html)
LT (1) LT3723858T (cg-RX-API-DMAC7.html)
PL (1) PL3723858T3 (cg-RX-API-DMAC7.html)
PT (1) PT3723858T (cg-RX-API-DMAC7.html)
RS (1) RS62848B1 (cg-RX-API-DMAC7.html)
SI (1) SI3723858T1 (cg-RX-API-DMAC7.html)
TW (1) TWI772724B (cg-RX-API-DMAC7.html)
WO (1) WO2020128049A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
TWI772724B (zh) 2018-12-21 2022-08-01 英商克馬伯有限公司 具有共同輕鏈的FIXaxFX雙專一性抗體
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies
WO2020229621A1 (en) * 2019-05-15 2020-11-19 Kymab Limited Improved lambda antibodies
CN115728433B (zh) * 2021-08-27 2024-11-15 联邦生物科技(珠海横琴)有限公司 IgG4型单克隆抗体电荷异质性的离子交换色谱检测方法
WO2023111018A1 (en) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Antibodies against coagulation factor x and uses thereof
WO2023147574A2 (en) * 2022-01-31 2023-08-03 The Children's Hospital Of Philadelphia Compositions and methods for treating factor ix deficiency
US12098400B2 (en) 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
GB202319967D0 (en) 2023-12-22 2024-02-07 Epsilogen Ltd Heteromultimeric proteins
WO2026036047A1 (en) * 2024-08-08 2026-02-12 Altus Enterprises, Inc. Antibody molecules to fixa and fx and uses thereof
WO2026037918A1 (en) 2024-08-14 2026-02-19 Epsilogen Ltd Heteromultimeric proteins

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2003271186A1 (en) 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EP2824183B1 (en) 2005-04-08 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing bispecific antibodies
CA2614076A1 (en) 2005-07-05 2007-01-11 Glaxo Group Limited Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
CA2650131A1 (en) * 2006-04-14 2007-10-25 Amgen Inc. Agonist erythropoietin receptor antibodies
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
AU2010336277B2 (en) * 2009-12-25 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Polypeptide modification method for purifying polypeptide multimers
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US20140356377A1 (en) 2011-08-25 2014-12-04 Umc Utrecht Holding B.V. Compounds for use in boosting coagulation
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CN104854133B (zh) 2012-10-12 2018-10-30 新加坡科技研究局 用于制备重组抗体治疗剂的最佳重链和轻链信号肽
CA2904805A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
EP3065768B1 (en) 2013-11-04 2020-09-23 The Regents of the University of California Composition for use in treatment or prevention of conditions associated with bleeding or hypocoagulationcompostion
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
TW201625299A (zh) 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
CA2978038A1 (en) 2015-04-17 2016-10-20 F. Hoffmann-La Roche Ag Combination therapy with coagulation factors and multispecific antibodies
JP2018123055A (ja) 2015-04-24 2018-08-09 公立大学法人奈良県立医科大学 血液凝固第viii因子(fviii)の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第xi因子(fxi)異常症の予防および/または治療に用いられる医薬組成物
WO2016207402A1 (en) * 2015-06-26 2016-12-29 Institute For Research In Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
JP6920293B2 (ja) 2015-10-30 2021-08-18 メドイミューン・リミテッドMedImmune Limited IgG軽鎖におけるN末端切断の防止
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
WO2017132827A1 (en) * 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
JP7014724B2 (ja) 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Fab免疫グロブリンおよびその使用
SG11201809642TA (en) 2016-05-16 2018-11-29 Baxalta Inc Anti-factor ix padua antibodies
CA3027018A1 (en) * 2016-07-29 2018-02-01 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
US11352438B2 (en) 2016-09-06 2022-06-07 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
AU2017363309A1 (en) * 2016-11-23 2019-07-11 Bioverativ Therapeutics Inc. Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
AU2018216008A1 (en) 2017-02-01 2019-08-01 Novo Nordisk A/S Procoagulant antibodies
WO2018145125A1 (en) 2017-02-06 2018-08-09 Applied Stemcell, Inc. Coagulation factor viii mimetic protein and uses thereof
EP3615574B1 (en) * 2017-04-26 2026-06-24 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
WO2018209265A1 (en) 2017-05-11 2018-11-15 Atreca, Inc. Anti-malarial antibodies that bind circumsporozoite protein
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CA3071236A1 (en) 2017-09-29 2019-04-04 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient
CN111386285B (zh) 2017-11-15 2024-08-27 诺和诺德股份有限公司 增强fx活化的因子x结合物
TWI772724B (zh) * 2018-12-21 2022-08-01 英商克馬伯有限公司 具有共同輕鏈的FIXaxFX雙專一性抗體

Also Published As

Publication number Publication date
BR112021012065A2 (pt) 2021-12-07
HUE057634T2 (hu) 2022-05-28
US20200199250A1 (en) 2020-06-25
US20220064327A1 (en) 2022-03-03
HRP20220088T1 (hr) 2022-04-15
JP2022515770A (ja) 2022-02-22
CN113453757A (zh) 2021-09-28
WO2020128049A1 (en) 2020-06-25
EP3723858B1 (en) 2021-10-27
CN113453757B (zh) 2024-06-28
KR20210118085A (ko) 2021-09-29
EP4015538A1 (en) 2022-06-22
JP7530362B2 (ja) 2024-08-07
SI3723858T1 (sl) 2022-04-29
RS62848B1 (sr) 2022-02-28
TW202039584A (zh) 2020-11-01
TWI772724B (zh) 2022-08-01
PL3723858T3 (pl) 2022-03-07
US10815308B2 (en) 2020-10-27
CA3123177A1 (en) 2020-06-25
EP3723858A1 (en) 2020-10-21
PT3723858T (pt) 2022-02-02
ES2901683T3 (es) 2022-03-23
US20210101997A1 (en) 2021-04-08
LT3723858T (lt) 2022-02-10
US11976135B2 (en) 2024-05-07

Similar Documents

Publication Publication Date Title
HUE057634T2 (hu) FIXAXFX bispecifikus ellenanyag közös könnyûlánccal
KR102763158B9 (ko) 최적화된 항tl1a 항체
IL287035A (en) Anti-ige antibodies
EP3941944A4 (en) BISPECIFIC CLAUDIN-6 ANTIBODIES
EP3880227A4 (en) ANTI-CD25 ANTIBODIES
EP3763743A4 (en) BISPECIFIC ANTIBODY
IL289252A (en) Ep2 antagonist
EP4081547A4 (en) Novel anti-fgfr2b antibodies
EP3768724A4 (en) NEW ANTI-PD-1 ANTIBODIES
EP3794275C0 (en) LED LIGHTING DEVICE
DK3844059T3 (da) Kædestrammer med kædeomskifter
IL304800A (en) Bispecific antibody
PT3765788T (pt) Luminária ligada
EP4081539A4 (en) Novel anti-fgfr2b antibodies
IL281594A (en) Anti-klrg1 antibodies
EP4144370A4 (en) BISPECIFIC ANTIBODY
IL292799A (en) Anti-siglec-9 antibody molecules
EP4097139A4 (en) PLAP-CD3 EPSILON BISPECIFIC ANTIBODIES
EP3891180C0 (en) HUMANIZED ANTIBODIES AGAINST IL17BR
EP3973275C0 (en) AUTOMATIC FOCUS LIBS SYSTEM
EP3803020A4 (en) DRIVE CHAIN ELEMENT
EP3807061A4 (en) BLOCKCHAIN WITH MONOLITHIC LINKS
EP3765389C0 (en) CHAIN CONVEYOR CURVE
DK3611404T3 (da) Kædetandhjul
DE102019129616A8 (de) Kettenantriebsmechanismus